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 Abstract 
    In females, estrogens play pivotal roles in preventing excess body weight (BW) gain. 
On the other hand, the roles of androgens in female BW, appetite, and energy metabolism 
have not been fully examined. We hypothesized that androgens’ effects on food intake 
(FI) and BW regulation change according to the estrogens’ levels. To evaluate this 
hypothesis, the effects of chronic testosterone administration in ovariectomized (OVX) 
female rats with or without estradiol supplementation were examined in this study. 
Chronic testosterone administration decreased BW, FI, white adipose tissue (WAT) 
weight, and adipocyte size in OVX rats, whereas it increased BW, WAT weight, and 
adipocyte size in OVX with estradiol-administered rats. In addition, chronic testosterone 
administration increased hypothalamic CYP19a1 mRNA levels in OVX rats, whereas it 
did not alter CYP19a1 mRNA levels in OVX with estradiol-administered rats, indicating 
that conversion of testosterone to estrogens in the hypothalamus may be activated in 
testosterone-administered OVX rats. Furthermore, chronic testosterone administration 
decreased hypothalamic TNF-α mRNA levels in OVX rats, whereas it increased 
hypothalamic IL-1β mRNA levels in OVX with estradiol-administered rats. On the other 
hand, IL-1β and TNF-α mRNA levels in visceral and subcutaneous WAT and liver were 
not changed by chronic testosterone administration in both groups. These data indicate 
that the effects of chronic testosterone administration on BW, FI, WAT weight, and 
adipocyte size were changed by estradiol treatment in female rats. Testosterone has 
facilitative effects on BW gain, FI, and adiposity under the estradiol-supplemented 
condition, whereas it has inhibitory effects in the non-supplemented condition. 
Differences in the responses of hypothalamic factors, such as aromatase and 
inflammatory cytokines, to testosterone might underlie these opposite effects. 
 Introduction 
    Energy balance and reproductive function are closely linked in most species. The 
sex hormones, estrogens and androgens, are particularly related in the regulation of 
food intake (FI), energy metabolism, and body weight (BW) in mammals and humans 
(Hirschberg, 2012). Ovariectomy increases FI and BW in female animals, and these 
effects are prevented by estradiol replacement, indicating that estrogens play pivotal 
roles in preventing excess BW gain in females (Asarian and Geary, 2013; Blaustein 
and Wade, 1976; Hirschberg et al., 2012). These estrogens’ effects on BW are 
primarily mediated by estrogen receptor-α (ER-α) in the hypothalamic area and brain 
stem. Estradiol injection into the hypothalamic paraventricular nucleus decreases BW 
and FI in ovariectomized rats (Palmer et al., 1986; Butera et al., 1989). Mutations of 
ER-α genes induce obesity in humans and mice, and deletion of ER-α blocks the 
effects of estradiol on BW (Heine et al., 2000; Okura et al., 2003; Gao et al., 2007). 
    On the other hand, the roles of androgens in female FI, energy metabolism, and 
BW regulation have not been fully examined, although some studies have shown that 
androgens increase FI and fat weight in females (Hirschberg et al., 2004; Naessen et 
al., 2007; Lim et al., 2009; Hirschberg, 2012) and increase the risk of visceral obesity 
in women and experimental animals (Evans et al., 1988; Dieudonne et al, 1998; 
Ibanez et al., 2003; Gambineri et al., 2004; Nohara et al., 2014). Androgen-
administered animals have been used as a model of polycystic ovary syndrome 
(PCOS), which is one of the common causes of anovulation and metabolic 
abnormalities in women of reproductive age, because these animals show disruption 
 of ovulation, as well as increased BW and fat mass (Walters et al., 2012). However, 
the physiological mechanisms by which androgens disturb FI and BW regulation in 
females at this age have not been fully evaluated. Interestingly, it has been reported 
that the effects of androgens on energy metabolism and BW in males are different 
from those in females of reproductive age. Deficiency of testosterone, one of the most 
important androgens, increases the amount of visceral adipose tissue and insulin 
resistance in males, and it increases the risk of diabetes and metabolic syndrome 
(Navarro et al., 2015). These data suggest that testosterone plays pivotal roles in 
preventing excess BW gain and obesity in males. 
    In a previous study, we evaluated the effects of chronic testosterone 
administration on BW, FI, and body composition in female rats of different 
reproductive ages and gonadal status, i.e., pre-pubertal age, ovarian-intact 
reproductive age, and ovariectomized reproductive age (Iwasa et al., 2016). We found 
that BW gain and FI were increased by chronic testosterone administration in pre-
pubertal and ovarian-intact reproductive age rats, but not in ovariectomized rats. In 
this study, all ovariectomized rats showed undetectable levels of serum estradiol, 
whereas 25% of pre-pubertal rats showed detectable levels of serum estradiol 
(unpublished data). In addition, because the ovaries were not removed in pre-pubertal 
rats, other kinds of estrogen may be produced and secreted into the plasma. Thus, it 
is speculated that pre-pubertal rats may have higher estrogen levels than 
ovariectomized rats. Therefore, we hypothesized that testosterone’s effects on FI and 
BW regulation may be changed by the estrogen level. 
    To further investigate this hypothesis, we evaluated the effects of chronic 
administration of testosterone in ovariectomized female rats with or without estradiol 
supplementation in this study. Because estradiol could be stably supplemented, the 
interaction between testosterone and estradiol may be more precisely evaluated in this 
model. The effects on BW, FI, body composition, histological findings of fat and liver 
were evaluated. In addition, the peripheral and hypothalamic orexigenic factor, 
neuropeptide Y (NPY), and anorexigenic factors, leptin, proopiomelanocortin 
(POMC), and leptin receptor (OBRb), were evaluated, because it has been reported 
that sex steroids affect serum and hypothalamic levels and actions of these factors 
(Kimura et al., 2002; Anukulkitch et al., 2007; Santollo and Eckel, 2008; Li et al., 
2016). Hypothalamic estrogen and androgen receptors and aromatase gene 
expressions were also measured, because these factors also play pivotal roles in the 
regulation of BW and FI (Jones et al., 2000; Wu et al., 2009; Hirschberg, 2012). 
Furthermore, gene expressions of peripheral and hypothalamic pro-inflammatory 
cytokines were also measured, because these factors were involved in the disruption 
of the regulation of BW and FI in the obesity models, including the model induced by 
ovariectomy (Carvalheira et al., 2003; De Souza et al., 2005; Rogers et al., 2009; 
Thaler et al., 2013). 
Materials and Methods 
Animals 
    Eight-week-old Wistar female adult rats (200-230 g) were purchased from 
 Charles River Laboratories Japan, Inc. (Kanagawa, Japan) and housed in a room 
under controlled light (12 h light, 12 h darkness; lights turned on at 0800 and turned 
off at 2000) and temperature (24°C) with free access to food and water. In total, 32 
rats were used in this study. All animal experiments were conducted in accordance 
with the ethical standards of the institutional Animal Care and Use Committee of the 
University of Tokushima. Ovariectomy was carried out under sodium pentobarbital 
(60-80 mg/kg, intraperitoneal, i.p.), and tube implantations and decapitation were 
carried out under sevoflurane anesthesia. At nine weeks of age, rats were 
ovariectomized bilaterally and individually housed after surgery. Water containing 
ibuprofen (0.1 mg/ml) was provided during the three days after surgery to reduce the 
rats’ postoperative pain. 
 
Effects of chronic testosterone administration in ovariectomized (OVX) rats not 
administered estradiol 
    Four weeks after ovariectomy (13 weeks of age), rats were randomly divided 
into either the testosterone-administered (Testosterone) or the without testosterone-
administered (Control) group (n = 8 per group). In the Testosterone group, rats were 
implanted with a silastic tube filled with crystalline testosterone (inner diameter 3 
mm, outer diameter 5 mm, length of the filling part 30 mm) (As One Co., Ltd., Tokyo, 
Japan) (De Vries et al., 1994). In the Control group, rats were implanted with an 
empty tube. At 16 days after implantation, the rats were sacrificed by decapitation 
after measurement of BW and cumulative FI. The fixed amount of normal diet (type 
 MF; Oriental Yeast Co. Ltd., Tokyo, Japan) (359 kcal/100 g) was placed in the food 
space of the wire mesh top, and the remaining food weight was measured 16 days 
after implantation. Wood chip bedding was changed eight days after implantation, 
and broken food in the bedding was collected at this time point and 16 days after 
implantation, and their weights were added to the remaining food weight. Brain, 
blood, visceral fat (parametrial, perirenal, and mesenteric depots, subcutaneous fat 
(inguinal depot), liver, and uterus were collected. Weights of visceral fat, 
subcutaneous fat, and uterus were measured immediately after removal, and tissue 
samples (around 300-400-mm3) of visceral (parametrial) and subcutaneous fat were 
dissected. Similarly, the same sizes of tissue samples were dissected from the liver. 
Serum was separated by centrifugation and stored at –20°C, and tissue samples were 
stored at –80°C.  Other tissue samples of visceral and subcutaneous fat and liver 
were fixed in 4% paraformaldehyde. 
 
Effects of chronic testosterone administration in ovariectomized with estradiol-
administered (OVX+E) rats 
    Four weeks after ovariectomy (13 weeks of age), all rats were implanted with a 
silastic tube filled with crystalline estradiol (length of the filling part, 3 mm) (Le et 
al., 2014). At the same time, rats were divided into either the Testosterone or the 
Control group, as described above (n = 8 per group). At 16 days after implantation, 
the rats were sacrificed by decapitation after measurement of BW and cumulative FI. 
Tissue weight were measured, and samples were collected and stored or fixed, as 
 described above. 
 
Hormone assay 
    Serum estradiol and testosterone levels were measured by a commercial 
laboratory (SRL, Tokyo, Japan) using an electrochemiluminescence immunoassay 
(ECLIA; Roche Diagnostics GmbH, Mannheim, Germany). Serum leptin levels were 
measured using radioimmunoassay kits (multi-species leptin RIA kit, Linco Research 
Inc., MO, USA). The sensitivity of the assay was 1.0 ng/ml, and its inter- and intra-
assay coefficients of variation were 3.2% and 7.8%, respectively. 
 
Quantitative real-time polymerase chain reaction 
    Whole hypothalamic explants were dissected from the frozen brains, as 
described previously (Iwasa et al., 2016). Briefly, the brain sections were dissected 
out via an anterior coronal cut at the posterior border of the mammillary bodies, 
parasagittal cuts along the hypothalamic fissures, and a dorsal cut 2.5 mm from the 
ventral surface. Total RNA was isolated from hypothalamic explants and visceral fat 
using a TRIzol® reagent kit (Invitrogen Co., Carlsbad, CA, USA) and an RNeasy® 
mini kit (Qiagen Gmbh, Hilden, Germany). Then, cDNA was synthesized with oligo 
(deoxythymidine) primers at 50°C using the SuperScript III first-strand synthesis 
system for the real-time polymerase chain reaction (PCR; Invitrogen Co.). The PCR 
analysis was performed using the StepOnePlusTM real-time PCR system (PE 
Applied Biosystems, Foster City, CA, USA) and FAST SYBR® green. The ER-α 
 androgen receptor (AR), CYP19a1, NPY, POMC, OBRb, interleukin-1β (IL-1β), and 
tumor necrosis factor-α (TNF-α) mRNA levels in the hypothalamus, leptin, IL-1β, 
and TNF-α mRNA levels in visceral and subcutaneous WAT, and IL-1β and TNF-α 
mRNA levels in the liver were measured. The mRNA expression level of each factor 
was normalized to that of GAPDH or the 18S rRNA level. Dissociation curve 
analysis was also performed for each gene at the end of PCR. Each amplicon 
generated a single peak. Primer sequences, product size, and annealing temperatures 
are shown in Table 1. The PCR conditions were as follows: initial denaturation and 
enzyme activation at 95°C for 20 s, followed by 45 cycles of denaturation at 95°C 
for 3 s, and annealing and extension for 30 s. 
 
Histology 
    Fixed visceral and subcutaneous WAT and liver were dehydrated with ethanol 
and xylene and sliced into sections after being embedded in paraffin. Serial 4-μm-
thick sections were stained with hematoxylin and eosin (H&E), and histological 
findings were captured by a Zeiss Imager M2 microscope with AxioVision version 
4.8 acquisition software (Zeiss). The mean adipocyte area of 50 randomly selected 
adipocytes per specimen was determined using ImageJ software. 
 
Statistical analyses 
    All results are presented as means ± SEM values. Student’s t-test or the Mann-
Whitney U test was used for comparisons between the control and testosterone-
 administered groups within the OVX and OVX+E groups. P-values of < 0.05 were 
considered significant. Two-way analysis of variance (ANOVA) was used for 
comparison of the effects of testosterone administration between the OVX and 
OVX+E groups. Cohen’s d (small effect = 0.2, medium effect = 0.5, large effect = 
0.8), r (small effect = 0.1, medium effect = 0.3, large effect = 0.5), and Eta squared 
(η2) (small effect = 0.2, medium effect = 0.5, large effect = 0.8) are reported when 
analyses were undertaken by Student’s t-test, the Mann-Whitney U test, and ANOVA, 
respectively (small effect size = 0.2, medium = 0.5, large = 0.8). 
 
Results 
Serum estradiol and testosterone levels in each group 
    Serum estradiol levels were lower in the OVX groups than in the OVX+E 
groups (p < 0.01, r = 0.85) (Table 2). Serum testosterone levels were higher in the 
Testosterone-administered groups than in the Control groups. On the other hand, 
serum estradiol levels were not different between the OVX-Control and OVX-
Testosterone groups. Similarly, serum estradiol levels were not different between the 
OVX+E-Control and OVX+E-Testosterone groups. Serum testosterone levels were 
not different between the OVX-Testosterone and OVX+E-Testosterone groups. 
 
These results indicate that each hormone was administered adequately in this 
experimental protocol. 
 
 Effects of chronic testosterone administration on BW, FI, WAT weight, and 
uterine weight in OVX and OVX+E rats 
    In the OVX group, BW change (% of initial BW) after implantation was 
significantly smaller in the Testosterone group than in the Control group (p = 0.03, d 
= 1.21) (Fig. 1A). Cumulative FI (g / 100 g initial BW) after implantation was 
significantly less in the Testosterone group than in the Control group (p < 0.01, d = 
1.94) (Fig. 1B). The weights (g) of visceral WAT, subcutaneous WAT, and total WAT 
were significantly lower in the Testosterone group than in the Control group (visceral 
WAT, p < 0.01, d = 1.51; subcutaneous WAT, p = 0.01, d = 1.41; total WAT, p < 0.01, 
d = 1.66) (Fig. 1C-E). On the other hand, uterine weight (mg) was significantly 
greater in the Testosterone group than in the Control group (p < 0.01, d = 1.84) (Fig. 
1F). 
    In the OVX+E group, BW change (% of initial BW) after implantation was 
significantly higher in the Testosterone group than in the Control group (p = 0.02, d 
= 1.36) (Fig. 1G). On the other hand, cumulative FI (g/100 g initial BW) after 
implantation in the Testosterone group was not different from that in the Control 
group (Fig. 1H). The weights (g) of subcutaneous WAT and total WAT were 
significantly greater in the Testosterone group than in the Control group 
(subcutaneous WAT, p = 0.04, d = 1.14; total WAT, p = 0.05, d = 1.07) (Fig. 1J, K). 
Uterine weights (mg) were not different between the Testosterone group and the 
Control group (Fig. 1L). 
    The effects of testosterone administration on BW change (% of initial BW) and 
 cumulative FI (g/100 g initial BW) were significantly different between the OVX and 
OVX+E groups (BW change, F(1,31) = 126.9, p < 0.01, η2 = 0.75, FI; F(1,31) = 75.5, 
p < 0.01, η2 = 0.67). Similarly, the effects of testosterone administration on the weight 
of subcutaneous WAT, visceral WAT, and total WAT were significantly different 
between the OVX and OVX+E groups (subcutaneous WAT, F(1,31) = 42.8, p < 0.01, 
η2 = 0.50; visceral WAT, F(1,31) = 89.3, p < 0.01, η2 = 0.36; total WAT, F(1,31) = 
14.2, p < 0.01, η2 = 0.26). The effects of testosterone administration on uterine weight 
were significantly different between the OVX and OVX+E groups (F(1,31) = 162.4, 
p < 0.01, η2 = 0.69). 
 
 
Effects of chronic testosterone administration on the mRNA levels of 
hypothalamic factors in OVX and OVX+E rats 
    In the OVX group, hypothalamic mRNA levels of CYP19a1 and NPY were 
significantly higher in the Testosterone group than in the Control group (CYP19a1, 
p < 0.01, d = 1.56; NPY, p = 0.04, d = 1.15) (Fig. 2, upper row). On the other hand, 
hypothalamic ER-α and TNF-α mRNA levels were significantly lower in the 
Testosterone group than in the Control group (ER-α, p = 0.01, d = 7.61; TNF-α, p = 
0.04, d = 1.08). Hypothalamic mRNA levels of AR, POMC, OBRb, and IL-1β were 
not different between the Testosterone and Control groups.  
    In the OVX+E group, hypothalamic ER-α and AR mRNA levels were 
significantly lower in the Testosterone group than in the Control group (ER-α, p = 
 0.03, r = 0.55; AR, p < 0.01, r = 0.84) (Fig. 2, lower row). On the other hand, the 
hypothalamic IL-1β mRNA level was significantly higher in the Testosterone group 
than in the Control group (p = 0.01, d = 1.43). Hypothalamic mRNA levels of 
CYP19a1, NPY, POMC, OBRb, and TNF-α were not different between the 
Testosterone and Control groups. 
    The effects of testosterone administration on the hypothalamic IL-1β and TNF-
α mRNA levels were significantly different between the OVX and OVX+E groups 
(IL-1β, F(1,31) = 7.62, p = 0.01, η2 = 0.16; TNF-α, F(1,31) = 7.22, p = 0.01, η2 = 
0.17). By contrast, the effects of testosterone administration on ER-α, AR, CYP19a1, 
IL-1β, and TNF-α were not significantly different between the OVX and OVX+E 
groups. 
 
Effects of chronic testosterone administration on serum leptin levels in OVX 
and OVX+E rats 
    In the OVX group, serum leptin levels were not different between the 
Testosterone and Control groups (Fig. 3A). The serum leptin level per unit of WAT 
(ng/mL/g) was significantly higher in the Testosterone group than in the Control 
group (p = 0.03, d = 1.23) (Fig. 3B). 
    In the OVX+E group, serum leptin levels were not different between the 
Testosterone and Control groups (Fig. 3C). The serum leptin level per unit of WAT 
was significantly lower in the Testosterone group than in the Control group (p = 0.04, 
d = 1.08) (Fig. 3D). 
     The effects of testosterone administration on the leptin level per unit of WAT 
were not significantly different between the OVX and OVX+E groups (F(1,31) = 
9.57, p < 0.01, , η2 = 0.20). 
 
Effects of chronic testosterone administration on the mRNA levels of 
inflammatory factors and adipocyte size in visceral WAT in OVX and OVX+E 
rats 
    In the OVX group, visceral WAT mRNA levels of leptin, IL-1β, and TNF-α were 
not different between the Testosterone and Control groups (Fig. 4A). Mean adipocyte 
size (μm2) was not different between the Testosterone and Control groups (Fig. 4B, 
C). 
    In the OVX+E group, visceral WAT mRNA levels of leptin, IL-1β, and TNF-α 
were not different between the Testosterone and Control groups (Fig. 4D). Mean 
adipocyte size was significantly larger in the Testosterone group than in the Control 
group (p < 0.01, r = 0.07) (Fig. 4E, F). 
    The effects of testosterone administration on adipocyte size of visceral WAT 
were significantly different between the OVX and OVX+E groups (F(1,1599) = 89.9, 
p < 0.01, , η2 = 0.05). 
 
Effects of chronic testosterone administration on the mRNA levels of 
inflammatory factors and adipocyte size in subcutaneous WAT in OVX and 
OVX+E rats 
     In the OVX group, subcutaneous WAT mRNA levels of leptin, IL-1β, and TNF-
α were not different between the Testosterone and Control groups (Fig. 5A). Mean 
adipocyte size (μm2) was significantly smaller in the Testosterone group than in the 
Control group (p < 0.01, r = 0.30) (Fig. 5B, C). 
    In the OVX+E group, subcutaneous WAT mRNA levels of leptin, IL-1β, and 
TNF-α were not different between the Testosterone and Control groups (Fig. 5D). 
Mean adipocyte size was not different between the Testosterone group and the 
Control group (Fig. 5E, F). 
    The effects of testosterone administration on adipocyte size of subcutaneous 
WAT were significantly different between the OVX and OVX+E groups (F(1,1599) 
= 825.6, p < 0.01, , η2 = 0.33). 
 
Effects of chronic testosterone administration on the mRNA levels of 
inflammatory factors in liver in OVX and OVX+E rats 
    In the OVX group, IL-1β and TNF-α mRNA levels in liver were not different 
between the Testosterone and Control groups (Fig. 6A). There were no obvious 
differences in microscopic findings of the liver between the Testosterone and Control 
groups (Fig. 6B). 
    In the OVX+E group, IL-1β and TNF-α mRNA levels in the liver were not 
different between the Testosterone and Control groups (Fig. 6C). There were no 
obvious differences in the microscopic findings of the liver between the Testosterone 
and Control groups (Fig. 6D). 
  
Discussion 
    In the present study, chronic testosterone administration decreased BW, FI, and 
WAT weight in OVX rats, whereas it increased BW and WAT weight in OVX+E rats. 
Similarly, chronic testosterone administration decreased subcutaneous adipocyte size 
in OVX rats, whereas it increased visceral adipocyte size in OVX+E rats. These 
results indicate that the effects of testosterone on BW and adipocytes in OVX rats 
were completely opposite to those in OVX+E rats. Sex hormones play pivotal roles 
in the regulation of FI, energy metabolism, and BW in mammals and humans 
(Hirschberg, 2012). Many studies have indicated that estrogens prevent excess BW 
gain mainly through the modification of central and peripheral factors, such as 
increased leptin secretion and hypothalamic OBRb and POMC gene expressions and 
decreased hypothalamic NPY gene expression and action (Kimura et al., 2002; 
Blaustein and Wade, 1976; Anukulkitch et al., 2007; Santollo and Eckel, 2008; 
Hirschberg et al., 2012; Santollo et al., 2012; Asarian and Geary, 2013), whereas the 
roles of androgens in the regulation of BW, FI, and energy metabolism and their 
mechanisms have not been fully examined. Some studies have suggested that chronic 
administration of androgens, such as testosterone, increases BW and body fat in 
female experimental animals at reproductive age (Walters et al., 2012), and that 
hyperandrogenism is related to the dysfunctions of BW and metabolic regulation in 
women (Golden et al., 2004; Coviello et al., 2006; Navarro et al., 2015). On the other 
hand, as noted above, the effects of androgens on BW and energy metabolism in males 
 do not correspond to those in females. Androgens prevent excess BW gain, obesity, 
and insulin resistance, and these actions decrease the risk of diabetes and metabolic 
syndrome in males (Navarro et al., 2015). Thus, we hypothesized that testosterone, 
one of the important androgens, prevents the inhibitory action of estrogen on BW gain, 
FI, and adiposity, and that it induces facilitative effects on them only in the presence 
of estrogen. Our previous data, which showed that the effects of chronic testosterone 
administration on BW and FI were changed by reproductive age and gonadal status, 
partially support this hypothesis (Iwasa et al., 2016). However, because gonadal-intact 
rats were used and serum estrogens levels were not evaluated in that study, the 
possibility that testosterone only suppressed estrogens secretion from the ovary, but 
not estrogens’ actions, could not be excluded. Therefore, ovariectomized with 
estradiol-supplemented rats were used in the present study, and serum estradiol levels 
were not different between control rats and testosterone-administered rats; 
nevertheless, chronic testosterone administration increased BW and WAT weight. 
These results may support our hypothesis that testosterone has facilitative effects on 
BW gain and adiposity by preventing the inhibitory action of estrogens. 
    On the other hand, there are some discrepancies in the results between the present 
and our previous studies. For example, chronic testosterone administration did not 
affect FI in OVX+E rats in the present study, whereas it increased FI in gonadal intact 
female rats in a previous study (Iwasa et al., 2016). Because the mean serum estradiol 
level in OVX+E rats used in this study (143.9±29.2 pg/mL) was higher than that in 
gonadal intact female rats used in a previous study (45.9±7.8 pg/mL, unpublished 
 data), it may be assumed that the administered testosterone could not overcome the 
anorectic effects of estradiol in the present study. Besides this, differences in the study 
protocol, such as the duration of estradiol/testosterone administration, may have 
induced the discrepant results between the present and previous studies. 
    As mentioned above, chronic testosterone administration decreased BW, FI, and 
WAT weight in OVX rats in the present study. Because testosterone administration 
increased uterine weight in OVX rats, but not in OVX+E rats, conversion of 
testosterone to estrogens may be activated in OVX rats. Although serum estradiol 
levels in testosterone-administered OVX rats were not different from those in OVX 
rats not administered testosterone, other kinds of estrogens might be increased by 
testosterone administration. If so, it is possible that converted estrogens attenuate BW 
gain and WAT accumulation. 
    In the present study, chronic testosterone administration increased hypothalamic 
CYP19a1 mRNA levels in OVX rats, whereas it did not alter CYP19a1 mRNA levels 
in OVX+E rats. Thus, these results indicate that conversion from testosterone to 
estradiol in the brain may be increased in OVX rats compared with OVX+E rats. It 
has been reported that hypothalamic estrogens that are converted from testosterone 
by aromatase play roles in preventing BW gain, and that knockout of the aromatase 
gene induces obesity in male and female rodents (Jones et al., 2000; Wu et al., 2009). 
Therefore, we hypothesize that brain aromatase might be activated under the chronic 
testosterone-administered condition in OVX rats, and that converted estrogens acted 
to suppress the BW gain and FI and prevented accumulation of WAT in the present 
study. 
    In the present study, chronic testosterone administration decreased hypothalamic 
AR mRNA levels in OVX+E rats, whereas it did not alter AR mRNA levels in OVX 
rats. It remains unclear whether this AR change is involved in the BW gain and 
increased WAT weights in testosterone-administered OVX+E rats. No study has 
evaluated the effects of exogenous testosterone on the hypothalamic AR levels in both 
sexes. On the other hand, some studies have shown that AR-knockout male and 
female mice show late-onset obesity and diet-induced obesity by modulation of lipid 
metabolism, respectively (Sato et al., 2003; Fagman et al., 2015). In addition, it has 
been shown that aromatase activity and mRNA in the brain are regulated primarily by 
androgens via AR in mammals, and that a potential androgen-responsive element is 
present at brain specific aromatase (Abdelgadir et al., 1994; Honda et al., 1994; Veney 
and Rissman, 2000; Roselli et al., 2001, 2009). Give this background, one possibility 
is that a decrease of AR itself is related to the increases of BW gain and WAT weight 
in the OVX+E rats in the present study. Another possibility is that decreased AR 
disrupts the response of aromatase to administered testosterone in OVX+E rats and 
induces the changes noted above. 
    In the present study, chronic testosterone administration decreased hypothalamic 
TNF-α mRNA levels in OVX rats, whereas it increased hypothalamic IL-1β mRNA 
levels in OVX+E rats. On the other hand, IL-1β and TNF-α mRNA levels in visceral 
and subcutaneous WAT and liver were not changed by chronic testosterone 
administration in both groups. It has been reported that systemic low-grade 
 inflammation is observed in obese individuals, and that these alterations are related 
in some metabolic diseases (Bastard et al., 2006; Rogers et al., 2009). In particular, 
inflammation in the hypothalamus produces defective FI and obesity through 
hypothalamic insulin and leptin resistance (Carvalheira et al., 2003; De Souza et al., 
2005; Thaler et al., 2013). Thus, testosterone-induced alterations in hypothalamic 
cytokine levels, i.e., decreases in OVX rats and increases in OVX+E rats, might be 
partially involved in the changes of BW, FI, and WAT weight. 
    In the present study, chronic testosterone administration did not alter the serum 
leptin levels in both OVX rats and OVX+E rats. However, serum leptin levels per unit 
WAT were increased or decreased by chronic testosterone administration in OVX rats 
and OVX+E rats, respectively. These results show that testosterone alters leptin 
secretion from WAT, and that its actions are changed according to the estrogen 
treatment. Interestingly, it has been reported that leptin levels per unit WAT are also 
deceased in high-fat diet-induced obese rats (Ainslie et al., 2000), indicating that the 
mechanisms by which testosterone induces BW and FI under the presence of estradiol 
may be similar to those acting in diet-induced obesity. In this study, chronic 
testosterone administration increased hypothalamic NPY mRNA levels in OVX rats. 
Although it is possible that this alteration may be one of the counter regulatory actions 
to increase FI and BW gain, the precise physiological role of this change remains 
unclear. 
    The limitations of the present study are as follows. Serum testosterone levels in 
the testosterone-administered groups were near the physiological range of male rats 
 (De Vries et al., 1994), and they were supra-physiological levels for female rats. 
Therefore, it remains unclear whether the results of the present study reproduce the 
pathophysiology of women with hyperandrogenism. In addition, it needs to be 
carefully considered whether these results reflect the efficacy of treatments, such as 
hormone replacement therapy for menopausal women and anti-androgen therapy for 
PCOS women. 
    In summary, the effects of chronic testosterone administration on BW, FI, WAT 
weight, and adipocyte size changed according to estrogen treatment in female rats. 
Testosterone has facilitative effects on BW gain and adiposity under the estradiol-
supplemented condition, whereas it has inhibitory effects under the non-
supplemented condition. In other words, the beneficial effects of testosterone 
administration on BW and adiposity in OVX rats are prevented by estradiol 
administration. Differences in the responses of hypothalamic factors, such as 
aromatase and inflammatory cytokines, to testosterone might underlie these opposite 
effects. These results may support our hypothesis that testosterone has unfavorable 
effects on BW and energy metabolism by preventing the favorable actions of 
estrogens. 
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 Figure legends 
Fig. 1 
(A, G) Body weight (BW) change (% of initial BW), (B, H) cumulative food intake (FI) 
(g/100 g initial BW), (C, I) visceral white adipose tissue (WAT) weight (g/100 g BW), (D, 
J) subcutaneous WAT weight (g/100 g BW), (E, K) total WAT weight (g/100 g BW), and 
(F, L) uterine weight in control (□) and testosterone-administered (■) female rats. The 
upper row shows the results in ovariectomized (OVX) rats, and the lower row shows 
those in estradiol-administered OVX (OVX+E) rats. n = 8 per group. Data are expressed 
as means ± SEM. * P < 0.05, ** P < 0.01. 
 
Fig. 2 
Hypothalamic mRNA levels of ER-α, AR, CYP19a1, NPY, POMC, OBRb, IL-1β, and 
TNF-α in control (□) and testosterone-administered (■) female rats. The upper row 
shows the results in ovariectomized (OVX) rats, and the lower row shows those in 
estradiol-administered OVX (OVX+E) rats. The mRNA expression levels of control rats 
are expressed as 1.0. n = 8 per group. Data are expressed as means ± SEM. * P < 0.05, 
** P < 0.01. 
 
Fig. 3 
(A, C) Serum leptin levels and (B, D) serum leptin/total white adipose tissue (WAT) 
weight in control (□) and testosterone-administered (■) female rats. The upper row 
shows the results in ovariectomized (OVX) rats, and the lower row shows those in 
 estradiol-administered OVX (OVX+E) rats. n = 8 per group. Data are expressed as means 
± SEM. * P < 0.05. 
 
Fig. 4 
(A, D) Visceral adipose mRNA levels of leptin, IL-1β, and TNF-α, (B, E) representative 
photomicrographs of visceral adipose tissues with H&E staining, and (C, F) area of 
adipocytes in control (□) and testosterone-administered (■) female rats. The upper row 
shows the results in ovariectomized (OVX) rats, and the lower row shows those in OVX 
with estradiol-administered (OVX+E) rats. n = 8 per group. Data are expressed as means 
± SEM. * P < 0.01. Bars in B and E = 100 μm. Images captured at 40 X. 
 
Fig. 5 
(A, D) Subcutaneous adipose mRNA levels of leptin, IL-1β, and TNF-α, (B, E) 
representative photomicrographs of visceral adipose tissues with H&E staining, and (C, 
F) area of adipocytes in control (□) and testosterone-administered (■) female rats. The 
upper row shows the results in ovariectomized (OVX) rats, and the lower row shows 
those in estradiol-administered OVX (OVX+E) rats. n = 8 per group. Data are expressed 
as means ± SEM. * P < 0.01. Bars in B and E = 100 μm. Images captured at 40 X. 
 
Fig. 6 
(A, C) Hepatic mRNA levels of IL-1β and TNF-α, and (B, D) representative 
photomicrographs of hepatic tissues with H&E staining in control (□) and testosterone-
 administered (■) female rats. The upper row shows the results in ovariectomized (OVX) 
rats, and the lower row shows those in estradiol-administered OVX (OVX+E) rats. n = 8 
per group. Data are expressed as means ± SEM. Bars in B and E = 100 μm. Images 
captured at 40 X. 
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 Table 1    Primer sequences, product sizes, and annealing temperatures 
  
Primer Sequence Product size (bp) Annealing T (℃) 
ER-α forward CAT CGA TAA GAA CCG GAG GA 128 62 
ER-α reverse TCT GAC GCT TGT GCT TCA AC   
AR forward CCC ATC GAC TAT TAC TTC CC 58 63 
AR reverse TTA CGA GCT CCC AGA GTC AT   
CYP19a1 forward CTC CTC CTG ATT CGG AAT TGT <95 63 
CYP19a1 reverse TCT GCC ATG GGA AAT GAG AG   
NPY forward GGG GCT GTG TGG ACT GAC CCT 148 66 
NPY reverse GAT GTA GTG TCG CAG AGC GGA G   
POMC forward CCT CAC CAC GGA AAG CA 104 66 
POMC reverse TCA AGG GCT GTT CAT CTC C   
OBRb forward GCA GCT ATG GTC TCA CTT CTT TTG 113 63 
OBRb reverse GTT CCC TGG GTG CTC TGA   
IL-1β forward GCT GTG GCA GCT ACC TAT GTC TTG 120 61 
IL-1β reverse AGG TCG TCA TCA TCC CAC GAG   
TNF-α forward AGC CCT GGT ATG AGC CCA TGT 109 65.5 
TNF-α reverse CCG GAC TCC GTG ATG TCT AAG T   
leptin forward GGT CAC CGG TTT GGA CTT CAT 64 66 
leptin reverse CTG GTC CAT CTT GGA CAA ACT CA   
GAPDH forward ATG GCA CAG TCA AGG CTG AGA 64 70 
GAPDH reverse CGC TCC TG GAA GAT GGT GAT   
18S rRNA forward GAC GGA CCA GAG CGA AAG C <65 64 
18S rRNA reverse AAC CTC CGA CTT TCG TTC TTG A   
 Table 2    Serum estradiol and testosterone levels in each group 
 Estradiol (pg / mL) Testosterone (ng / mL) 
OVX-Control 17.3 ± 1.7 UD 
OVX-Testosterone 17.1 ± 1.8 2.4 ± 0.16 
OVX+E
2
-Control 174.4 ± 55.6 UD 
OVX+E
2
-Testosterone 113.5 ± 17.6 2.4 ± 0.22 
 
Values are expressed as mean ± SEM 
UD : undetectable 
 
